U1

RONN Motor Group Announced the Merger and Takeover of LPHM is Nearly Completed

Retrieved on: 
Wednesday, March 15, 2023

Today, RONN Motor Group announced all significant filings have been completed, including the u-1 filing, which can be viewed at, https://www.sec.gov/Archives/edgar/data/58411/000139390523000118/lphm_1u...

Key Points: 
  • Today, RONN Motor Group announced all significant filings have been completed, including the u-1 filing, which can be viewed at, https://www.sec.gov/Archives/edgar/data/58411/000139390523000118/lphm_1u...
    RONN Motor Group is a multi-National hydrogen solution company that innovates mobility, stationary, and marine applications.
  • "We believe hydrogen solutions can make a significant difference in a cleaner future beyond just mobility," Ronn Ford, CEO & Founder of RONN.
  • Investors are cautioned that all forward-looking statements involve risks and uncertainties, including without limitation, the ability of RONN Motor Group to accomplish its stated plan of business.
  • Considering the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by RONN Motor Group or any other person.

DGAP-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

Retrieved on: 
Thursday, August 18, 2022

In the second quarter of 2022, the wind-down costs related to our first-generation vaccine candidate, CVnCoV, still impacted our financial position but continue to decrease as we conclude our remaining commitments, said Pierre Kemula, Chief Financial Officer of CureVac.

Key Points: 
  • In the second quarter of 2022, the wind-down costs related to our first-generation vaccine candidate, CVnCoV, still impacted our financial position but continue to decrease as we conclude our remaining commitments, said Pierre Kemula, Chief Financial Officer of CureVac.
  • Moving into the second half of 2022, we are further broadening our mRNA technology platform and advancing our programs in prophylactic vaccines as well as executing on our core strategy in oncology.
  • CureVac is delivering on its previously announced 2022 clinical development program in prophylactic vaccines by initiating a Phase 1 study with the modified COVID-19 mRNA vaccine candidate CV0501.
  • In the first quarter of 2022, CureVac received a 10 million milestone payment related to the start of the seasonal influenza clinical trial.

DGAP-News: CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

Retrieved on: 
Tuesday, July 5, 2022

CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale or distribution of Comirnaty by BioNTech and its partner Pfizer.

Key Points: 
  • CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale or distribution of Comirnaty by BioNTech and its partner Pfizer.
  • The CureVac intellectual property portfolio protects multiple inventions that are considered essential to the design and development of BioNTechs SARS CoV-2 mRNA vaccine, among others.
  • CureVac considers the rapid development of these vaccines a tremendous achievement, with unprecedented positive impact for global public health.
  • This achievement is based on decades of scientific research and innovation, supported by CureVac as the earliest pioneer in mRNA technology.

Alpha Lithium Secures US$30 million Investment from Uranium One with Right to Invest Additional US$185 million at Tolillar Salar, Argentina

Retrieved on: 
Monday, November 29, 2021

Alpha has formed a wholly owned subsidiary, Alpha One Lithium B.V. (Alpha One), which will be the sole owner of Alpha Lithium Argentina S.A., which in turn, will own only the Tolillar assets.

Key Points: 
  • Alpha has formed a wholly owned subsidiary, Alpha One Lithium B.V. (Alpha One), which will be the sole owner of Alpha Lithium Argentina S.A., which in turn, will own only the Tolillar assets.
  • Alpha will retain full control of Tolillar, management, and the board, and will be responsible for deploying the invested capital.
  • Upon completion of the Feasibility Study, U1 will have the option to acquire an additional 35% of Alpha One for US$185 million.
  • The Additional Consideration would be payable directly to the Company, which would imply a total value of US$743 million for the Tolillar asset.

Puritan (once again) beats Copan in German lawsuits and gets cost reimbursements too

Retrieved on: 
Monday, December 7, 2020

Eight years ago, Copan started litigation in Germany against Puritan back by filing a request for inspection proceedings with the District Court Dsseldorf based on German Utility Model1 DE 20 2004 021 787 U1 (Court-ref.

Key Points: 
  • Eight years ago, Copan started litigation in Germany against Puritan back by filing a request for inspection proceedings with the District Court Dsseldorf based on German Utility Model1 DE 20 2004 021 787 U1 (Court-ref.
  • In 2013, Copan filed complaints for infringement of three German Utility Models: DE 20 2004 021 787 U1, DE 20 2004 021 930 U1 and DE 20 2004 021 932 U1 (Court refs.
  • As an immediate countermeasure, Puritan filed for cancellation of all three German Utility Models at the German Patent and Trademark Office.
  • After eight years of litigation, Copan's three asserted German Utility Models have been declared null and void in their entirety.

Puritan (once again) beats Copan in German lawsuits and gets cost reimbursements too

Retrieved on: 
Monday, December 7, 2020

Eight years ago, Copan started litigation in Germany against Puritan back by filing a request for inspection proceedings with the District Court Dsseldorf based on German Utility Model1 DE 20 2004 021 787 U1 (Court-ref.

Key Points: 
  • Eight years ago, Copan started litigation in Germany against Puritan back by filing a request for inspection proceedings with the District Court Dsseldorf based on German Utility Model1 DE 20 2004 021 787 U1 (Court-ref.
  • In 2013, Copan filed complaints for infringement of three German Utility Models: DE 20 2004 021 787 U1, DE 20 2004 021 930 U1 and DE 20 2004 021 932 U1 (Court refs.
  • As an immediate countermeasure, Puritan filed for cancellation of all three German Utility Models at the German Patent and Trademark Office.
  • After eight years of litigation, Copan's three asserted German Utility Models have been declared null and void in their entirety.